News & Publications

News & Publications

Platinum-based therapies remain one of the mainstays of modern treatment regimens in clinical oncology. Latest research has demonstrated the targeted actions of platinums in killing cancer cells, and satraplatin in particular is a precision platinum for haemato-oncology indications.

Satraplatin Demonstrates High Cytotoxic Activity…

Satraplatin Demonstrates High Cytotoxic Activity…

Satraplatin is an oral pl​atinum analog with proven clinical efficacy and a more favorable toxicity profile, although with increased hematotoxicity, when compared to cisplatin…

Read more
The rediscovery of platinum-based cancer therapy

The rediscovery of platinum-based cancer therapy

Platinum (Pt) compounds entered the clinic as anticancer agents when cisplatin was approved in 1978. More than 40 years later, even in the era of precision medicine and immunotherapy…

Read more
Platinum-(IV)-derivative satraplatin…

Platinum-(IV)-derivative satraplatin…

Platinum-(IV)-derivative satraplatin represents a new generation of orally available anti-cancer drugs that are under development for the treatment of several cancers. Understanding the mechanisms of cell cycle modulation and apoptosis is…

Read more
Promising activity of nelfinavir-…

Promising activity of nelfinavir-…

Treatment of proteasome inhibitor (PI)-refractory multiple myeloma (MM) is challenging, with response rates of only 15% to 35% being achieved with next-generation drugs such as pomalidomide, carfilzomib, and daratumumab, alone…

Read more
Dayton Therapeutics Discovers New…

Dayton Therapeutics Discovers New…

Dayton Therapeutics has announced that the company is using its AI-powered genetic and molecular research model for investigating new therapeutic uses of clinical stage drug candidates where development has been discontinued – in particular satraplatin. Satraplatin is…

Read more
Dayton Therapeutics Discovers New…

Dayton Therapeutics Discovers New…

Dayton Therapeutics has announced that the company is using its AI-powered genetic and molecular research model for investigating new therapeutic uses of clinical stage drug candidates where development has been discontinued – in particular satraplatin. Satraplatin is…

Read more
Dayton Therapeutics Discovers New…

Dayton Therapeutics Discovers New…

Dayton Therapeutics has announced that the company is using its AI-powered genetic and molecular research model for investigating new therapeutic uses of clinical stage drug candidates where development has been discontinued – in particular satraplatin. Satraplatin is…

Read more
Dayton Therapeutics Discovers New…

Dayton Therapeutics Discovers New…

Dayton Therapeutics has announced that the company is using its AI-powered genetic and molecular research model for investigating new therapeutic uses of clinical stage drug candidates where development has been discontinued – in particular satraplatin. Satraplatin is…

Read more